Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul-Sep;20(3):185-189.
doi: 10.4103/aian.AIAN_241_17.

Levodopa: History and Therapeutic Applications

Sujith Ovallath  1 , Bahiya Sulthana  1
Affiliations

Levodopa: History and Therapeutic Applications

Sujith Ovallath et al. Ann Indian Acad Neurol. 2017 Jul-Sep.

Abstract

Levodopa - the aromatic amino acid L-3,4-dihydroxy phenylalanine has held the attention of neurologists and pharmacologists alike for more than half a century. Even though extensive research has been done across the globe in treatment of Parkinson's disease, with different molecules, none could replace the gold standard treatment or provide complete relief for the debilitated. Although research brought us better tips and tricks to modulate the dopamine blood levels to balance between the desired and deleterious effects, it could never replace the basic substrate. From simple oral preparation to more advanced treatment like duodenal dopa administration for better efficacy and compliance, L-dopa has sure undergone scrutiny and stayed strong as the fundamental neurotransmitter replacement therapy to pave path for many more new therapeutic strategies. So as a token of gratitude to the revolutionary agent and pioneers behind it, a trip down the memory lane is in order.

Keywords: Dopamine; history of levodopa; levodopa; newer levodopa.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Cotzias GC, Papavasiliou PS. Papavasiliou PS. Therapeutic studies of Parkinsonian patients: long term effects of D, L, and L Dopa. Brookhaven National Lab., Upton, NY; 1967 Jan 1
    1. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967;276:374–9. - PubMed
    1. Carlsson A, Lindqvist M, Magnusson TO. 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature. 1957;180:1200. - PubMed
    1. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord. 2008;23(Suppl 3):S497–508. - PubMed
    1. Bell EA, Janzen DH. Medical and ecological considerations of L-dopa and 5-HTP in seeds. Nature. 1971;229:136–7. - PubMed